SCHEMBL7180799

SCHEMBL7180799

Cc1cc(NC(=O)C(C#N)C(=O)C2CC2)ccc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.40
PDK1 Q15118 1/20 0.38
KDR P35968 10/20 0.37
BRAF P15056 6/20 0.37
AR P10275 2/20 0.37
USP30 Q70CQ3 1/20 0.37
CES2 O00748 1/20 0.37
ABCB11 O95342 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
GLA P06280 1/20 0.37
CYP3A4 P08684 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
CHRM1 P11229 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
TBXA2R P21731 1/20 0.37
AADAC P22760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9205909 0.76 PGR (0.35) AR
Laflunimus SCHEMBL9234178 0.75 DHODH (0.67) KDRBRAFUSP30LMNAEPHX2
Laflunimus SCHEMBL29677348 0.75 DHODH (0.67) KDRBRAFUSP30LMNAEPHX2
Laflunimus SCHEMBL21132 0.75 DHODH (0.67) KDRBRAFUSP30LMNAEPHX2
Laflunimus SCHEMBL22908 0.75 DHODH (0.67) KDRBRAFUSP30LMNAEPHX2
SCHEMBL13770863 0.74 MAPT (0.42) LMNACYP2C19SMN1; SMN2DHODHPOLB
SCHEMBL21369 0.74 EPHX1 (0.48) ALDH1A1LMNATSHRMAPK1HTT
SCHEMBL25134544 0.71 ALDH1A1 (0.40) IDO1KDRARALDH1A1LMNA
SCHEMBL17100730 0.70 DHODH (0.49) KDRBRAFARUSP30ALDH1A1
SCHEMBL21539519 0.70 DHODH (0.49) KDRBRAFARUSP30ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6566395-B1 Therapy of proliferative disorders, such as cancers, blood vessel disorders and fibrotic disorders by administering N-(3-methyl-4- trifluoromethylphenyl) 2-cyano-2-(cycloalkylcarbonyl)acetamide compounds BIOMEDICINES, INC. 2003-05-20 US disclosed